Pharma Industry

Consumer and patient protections are in two bills that have support of doctors in Congress.

Why lower-cost alternatives struggle to gain ground

An infectious disease specialist discusses the state of AMR, antimicrobial resistance, and why it is a threat to modern health care.

New report identifies ‘misalignment’ between research spending and chronic diseases that affect millions of people.

New tariffs of up to 200% could hit medications from the European Union and beyond, raising alarms over affordability, access and supply for physicians and patients.

FDA also publishes review letters in new drug approval process.

A review of more than 400,000 patients shows deprescribing works to reduce medication overload in overload adults, but effects on hospital visits and death are less clear.

If we want to remain the global leader in innovation, we need to keep a strong pricing system at home and use trade deals to push our allies to pay their fair share for the medical advances they rely on.

Out-of-pocket caps protect high spenders, but many others could see their drug costs rise.

Despite advocates and state actions, hard evidence is scant and there is no national consensus that cannabis is a medical treatment, scholars say.

Under new legislation, patients would get far fewer suggestions to ‘ask your doctor if…’

Experts examine drug pricing policies and potential effects of new tariffs on imports.

Medical groups warn of eroding trust, reduced access and insurance fallout after HHS bypasses expert vaccine advisory panel.

As digital clinics race to capitalize on the GLP-1 weight loss boom, concerns grow over quality, safety and the erosion of patient-centered care.

HHS announces plan to create ‘most-favored-nation’ cost scale so U.S. is not subsidizing drug prices in other countries.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

‘Wild west’ of pharmaceutical sales developed as patients clamor for GLP-1s for obesity treatment.

Novavax continues working with FDA, but case could signal a shift in broader vaccine procedures.